Research programme: antioxidants - Activus Pharma

Drug Profile

Research programme: antioxidants - Activus Pharma

Alternative Names: TA-264; TA-381

Latest Information Update: 22 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Activus Pharma
  • Developer Sosei
  • Class Quinolones
  • Mechanism of Action Antifibrinolytic agents; Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral vascular disorders; Stroke

Most Recent Events

  • 17 Aug 2010 Activus Pharma has been acquired and merged into Sosei
  • 17 Aug 2010 Activus Pharma has been acquired by Sosei
  • 21 Jun 2010 Sosei agrees to acquire Activus Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top